(Q34341681)

1 August 2017

title

Pharmacologic treatment options for obesity: what is old is new again (English)

1 reference

1 August 2017

0 references

Donna H Ryan

1

0 references

George A. Bray

series ordinal

2

object named as

George A Bray

1 reference

1 August 2017

publication date

1 June 2013

1 reference

Current Hypertension Reports

1 August 2017

published in

1 reference

1 August 2017

volume

15

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

182-189

1 reference

https://scigraph.springernature.com/pub.10.1007/s11906-013-0343-6

1 August 2017

exact match

0 references

cites work

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Cardiovascular disease risk factors, depression symptoms and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Lifestyle change and mobility in obese adults with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Bariatric surgery versus intensive medical therapy in obese patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Bariatric surgery versus conventional medical therapy for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Why do we need drugs to treat the patient with obesity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

The FDA's assessment of two drugs for chronic weight management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Serotonergic drugs and valvular heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Multicenter, placebo-controlled trial of lorcaserin for weight management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Effects on weight reduction and safety of short-term phentermine administration in Korean obese people

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Serotonergic drugs : effects on appetite expression and use for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0343-6

Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23625271

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11906-013-0343-6

1 reference

Dimensions Publication ID

1 August 2017

1015085098

0 references

1 reference